Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Drug:  veliparib
Find trials that include:  Any drugs shown
Results 1-25 of 29 for your search:
Start Over
Temozolomide with or without Veliparib in Treating Patients with Newly Diagnosed Glioblastoma Multiforme
Phase: Phase III, Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: A071102, NCI-2014-00616, CALGB-A071102, NCT02152982
Veliparib and Topotecan Hydrochloride in Treating Patients With Solid Tumors, Relapsed or Refractory Ovarian Cancer, or Primary Peritoneal Cancer
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: MC0861, NCI-2011-00312, 09-000742, CDR0000657976, MAYO-MC0861, 8329, NCT01012817
Veliparib With or Without Radiation Therapy, Carboplatin, and Paclitaxel in Patients With Stage III Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: S1206, NCI-2011-02592, CDR0000701003, CHNMC-PHII-111, PHII-111, 8811, NCT01386385
Veliparib, Radiation Therapy, and Temozolomide in Treating Younger Patients With Newly Diagnosed Diffuse Pontine Gliomas
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 21 and under
Trial IDs: PBTC-033, NCI-2012-00082, 12-C-0213, CDR0000717423, NCT01507324, P12978, NCT01514201
Veliparib and Combination Chemotherapy in Treating Patients With Metastatic Pancreatic Cancer
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 2009-608, NCI-2013-00656, NCT01489865
Cisplatin and Etoposide with or without Veliparib in Treating Patients with Extensive Stage Small Cell Lung Cancer or Metastatic Large Cell Neuroendocrine Non-small Cell Lung Cancer
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: E2511, NCI-2012-01985, CDR0000736704, ECOG-E2511, NCT01642251
Combination Chemotherapy with or without Veliparib in Treating Patients with Stage IV Head and Neck Cancer
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: A091101, NCI-2012-02009, NCT01711541
I-SPY 2 TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 097517, NCI-2015-00014, NCT01042379
Abiraterone Acetate and Prednisone With or Without Veliparib in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 12-0109, NCI-2012-01149, CDR0000730114, UCCRC-IL057, 9012, IL057, NCT01576172
Gemcitabine Hydrochloride and Cisplatin with or without Veliparib or Veliparib Alone in Patients with Locally Advanced or Metastatic Pancreatic Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 12-045, NCI-2012-00864, CDR0000732189, MSKCC-12-045, 8993, NCT01585805
Carboplatin and Combination Chemotherapy with or without Veliparib in Treating Patients with Stage IIA-IIIC Breast Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 12G.376, NCI-2013-00594, 2012001, 2012-47, 2997, NCT01818063
Molecular Profiling-Based Targeted Therapy in Treating Patients with Advanced Solid Tumors
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 13-C-0105, NCI-2013-01588, 130105, P121047, 9149, NCT01827384
Study Comparing Veliparib Plus FOLFIRI Versus Placebo Plus FOLFIRI With or Without Bevacizumab in Previously Untreated Metastatic Colorectal Cancer
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: M14-217, NCI-2015-00703, 2014-002866-65, NCT02305758
Carboplatin, Paclitaxel, Bevacizumab, and Veliparib in Treating Patients with Newly Diagnosed Stage II-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: GOG-9923, NCI-2011-03730, CDR0000656038, NCT00989651
Veliparib with or without Mitomycin C in Treating Patients with Metastatic, Unresectable, or Recurrent Solid Tumors
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: OSU 09100, NCI-2012-01473, CDR0000656393, 8472, NCT01017640
Veliparib and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients with Recurrent Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer or Metastatic Breast Cancer
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 10-01206, NCI-2012-03161, AECM-000248, 8475, 00-0248, NCT01145430
Cyclophosphamide and Veliparib in Treating Patients with Locally Advanced or Metastatic Breast Cancer
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 11-02-068, NCI-2011-02590, CDR0000700033, P8853_A18PAMDREVW01, 8853, AECM-11-02-068, NCT01351909
Veliparib, Paclitaxel, and Carboplatin in Treating Patients with Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery and Liver or Kidney Dysfunction
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: UPCI 10-115, NCI-2011-02500, CDR0000700997, 8808, NCT01366144
Veliparib and Dinaciclib with or without Carboplatin in Treating Patients with Advanced Solid Tumors
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 11-144, NCI-2011-03458, CDR0000710900, DFCI-11-144, 8484, NCT01434316
Start Over